S&P 500   3,699.12 (+0.88%)
DOW   30,218.26 (+0.83%)
QQQ   305.52 (+0.41%)
AAPL   122.25 (-0.56%)
MSFT   214.36 (+0.06%)
FB   279.70 (-0.76%)
GOOGL   1,823.76 (+0.11%)
AMZN   3,162.58 (-0.76%)
TSLA   599.04 (+0.95%)
NVDA   542.33 (+1.21%)
BABA   267.25 (+0.13%)
CGC   28.59 (-0.14%)
GE   10.88 (+2.64%)
MU   73.34 (+4.92%)
AMD   94.04 (+1.87%)
T   29.54 (+1.06%)
NIO   43.04 (-5.09%)
F   9.34 (+1.41%)
ACB   10.89 (-3.11%)
BA   232.71 (-1.89%)
NFLX   498.31 (+0.16%)
GILD   61.56 (+1.15%)
DIS   154.14 (+0.59%)
S&P 500   3,699.12 (+0.88%)
DOW   30,218.26 (+0.83%)
QQQ   305.52 (+0.41%)
AAPL   122.25 (-0.56%)
MSFT   214.36 (+0.06%)
FB   279.70 (-0.76%)
GOOGL   1,823.76 (+0.11%)
AMZN   3,162.58 (-0.76%)
TSLA   599.04 (+0.95%)
NVDA   542.33 (+1.21%)
BABA   267.25 (+0.13%)
CGC   28.59 (-0.14%)
GE   10.88 (+2.64%)
MU   73.34 (+4.92%)
AMD   94.04 (+1.87%)
T   29.54 (+1.06%)
NIO   43.04 (-5.09%)
F   9.34 (+1.41%)
ACB   10.89 (-3.11%)
BA   232.71 (-1.89%)
NFLX   498.31 (+0.16%)
GILD   61.56 (+1.15%)
DIS   154.14 (+0.59%)
S&P 500   3,699.12 (+0.88%)
DOW   30,218.26 (+0.83%)
QQQ   305.52 (+0.41%)
AAPL   122.25 (-0.56%)
MSFT   214.36 (+0.06%)
FB   279.70 (-0.76%)
GOOGL   1,823.76 (+0.11%)
AMZN   3,162.58 (-0.76%)
TSLA   599.04 (+0.95%)
NVDA   542.33 (+1.21%)
BABA   267.25 (+0.13%)
CGC   28.59 (-0.14%)
GE   10.88 (+2.64%)
MU   73.34 (+4.92%)
AMD   94.04 (+1.87%)
T   29.54 (+1.06%)
NIO   43.04 (-5.09%)
F   9.34 (+1.41%)
ACB   10.89 (-3.11%)
BA   232.71 (-1.89%)
NFLX   498.31 (+0.16%)
GILD   61.56 (+1.15%)
DIS   154.14 (+0.59%)
S&P 500   3,699.12 (+0.88%)
DOW   30,218.26 (+0.83%)
QQQ   305.52 (+0.41%)
AAPL   122.25 (-0.56%)
MSFT   214.36 (+0.06%)
FB   279.70 (-0.76%)
GOOGL   1,823.76 (+0.11%)
AMZN   3,162.58 (-0.76%)
TSLA   599.04 (+0.95%)
NVDA   542.33 (+1.21%)
BABA   267.25 (+0.13%)
CGC   28.59 (-0.14%)
GE   10.88 (+2.64%)
MU   73.34 (+4.92%)
AMD   94.04 (+1.87%)
T   29.54 (+1.06%)
NIO   43.04 (-5.09%)
F   9.34 (+1.41%)
ACB   10.89 (-3.11%)
BA   232.71 (-1.89%)
NFLX   498.31 (+0.16%)
GILD   61.56 (+1.15%)
DIS   154.14 (+0.59%)
Log in
NASDAQ:GLTO

Galecto Stock Forecast, Price & News

$14.26
-0.12 (-0.83 %)
(As of 12/4/2020 12:00 AM ET)
Add
Compare
Today's Range
$14.23
Now: $14.26▼
$14.61
50-Day Range N/A
52-Week Range
$13.32
Now: $14.26▼
$17.99
Volume5,226 shs
Average Volume59,817 shs
Market Capitalization$350.58 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB0139, an inhaled inhibitor of galectin-3 that is in Phase IIb clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis, a life-threatening progressive fibrotic disease of the lung. Its products also comprise GB2064, which is in Phase I/IIa for the treatment of myelofibrosis; and GB1211, a selective oral galectin-3 inhibitor that is in Phase I/IIa for the treatment of fibrosis related to non-alcoholic steatohepatitis, as well as development of other related indications, including cancer. Galecto, Inc. was founded in 2011 and is headquartered in Copenhagen, Denmark.

Beat the Market (BTM) Rank™

Analyst Opinion: 3.5Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank™

1.83 out of 5 stars


Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:GLTO
Previous Symbol
CUSIPN/A
CIKN/A
Webgalecto.com
Phone45 70 70 52 10
Employees20

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / Cash FlowN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

Outstanding Shares24,585,000
Market Cap$350.58 million
Next Earnings DateN/A
OptionableNot Optionable
$14.26
-0.12 (-0.83 %)
(As of 12/4/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive GLTO News and Ratings via Email

Sign-up to receive the latest news and ratings for GLTO and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Galecto (NASDAQ:GLTO) Frequently Asked Questions

Do Wall Street analysts recommend investors buy shares of Galecto?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Galecto in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Galecto or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Galecto?

Wall Street analysts have given Galecto a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Galecto wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

What price target have analysts set for GLTO?

3 Wall Street analysts have issued 1 year price targets for Galecto's stock. Their forecasts range from $27.00 to $29.00. On average, they expect Galecto's stock price to reach $28.00 in the next year. This suggests a possible upside of 96.4% from the stock's current price.
View analysts' price targets for Galecto.

Who are some of Galecto's key competitors?

Some companies that are related to Galecto include Ligand Pharmaceuticals (LGND), CytoDyn (CYDY), MacroGenics (MGNX), Epizyme (EPZM), Repare Therapeutics (RPTX), Phathom Pharmaceuticals (PHAT), Nkarta (NKTX), Rhythm Pharmaceuticals (RYTM), Travere Therapeutics (RTRX), Amneal Pharmaceuticals (AMRX), Endo International (ENDP), Zogenix (ZGNX), Athenex (ATNX), Cytokinetics (CYTK) and Northwest Biotherapeutics (NWBO).
View all competitors.

Who are Galecto's key executives?

Galecto's management team includes the following people:
  • Dr. Hans T. Schambye, Co-Founder & CEO (Age 55)
  • Mr. Ulf J. Nilsson, Co-Founder
  • Dr. Hakon Leffler, Co-Founder
  • Prof. Tariq Sethi M.D., B.Sc., M.A., Ph.D., FRCP, Co-Founder & Member of the Clinical Advisory Board - IPF
  • Mr. Jonathan P. Freve C.P.A., CPA, Chief Financial Officer (Age 42)
  • Mr. Anders Pedersen, Chief Operating Officer (Age 60)
  • Prof. Bertil Lindmark M.D., Ph.D., Chief Medical Officer (Age 55)

When did Galecto IPO?

(GLTO) raised $86 million in an initial public offering (IPO) on Thursday, October 29th 2020. The company issued 5,700,000 shares at a price of $14.00-$16.00 per share. BofA Securities, SVB Leerink and Credit Suisse served as the underwriters for the IPO and Kempen & Co. was co-manager.

What is Galecto's stock symbol?

Galecto trades on the NASDAQ under the ticker symbol "GLTO."

When does Galecto's quiet period expire?

Galecto's quiet period expires on Tuesday, December 8th. Galecto had issued 5,666,667 shares in its IPO on October 29th. The total size of the offering was $85,000,005 based on an initial share price of $15.00. During Galecto's quiet period, insiders and any underwriters that worked on the IPO are prevented from issuing any research reports for the company because of SEC regulations. Following the expiration of the company's quiet period, it's expected that the brokerages that served as underwriters on the stock will initiate research coverage on the company.

How do I buy shares of Galecto?

Shares of GLTO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Galecto's stock price today?

One share of GLTO stock can currently be purchased for approximately $14.26.

How big of a company is Galecto?

Galecto has a market capitalization of $350.58 million. Galecto employs 20 workers across the globe.

What is Galecto's official website?

The official website for Galecto is galecto.com.

How can I contact Galecto?

Galecto's mailing address is GALECTO BIOTECH AB OLE MAALOES VEJ3, COPENHAGEN G7, DK-2200. The company can be reached via phone at 45 70 70 52 10.

This page was last updated on 12/4/2020 by MarketBeat.com Staff
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.